» Articles » PMID: 31966075

Immunohistochemical-based Molecular Subtyping of Colorectal Carcinoma Using Maspin and Markers of Epithelial-mesenchymal Transition

Overview
Journal Oncol Lett
Specialty Oncology
Date 2020 Jan 23
PMID 31966075
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the present study was to classify colorectal carcinoma (CRC) into molecular subtypes, based on immunohistochemical (IHC) assessments. A total of 112 CRC samples were molecularly classified based on the expression levels of epithelial-mesenchymal transition (EMT)-associated IHC markers. A total of three molecular subtypes were defined: Epithelial, membrane positivity for E-cadherin and β-catenin, negative for vimentin; mesenchymal, E-cadherin-negative, nuclear β-catenin- and vimentin-positive; and hybrid cases, epithelial tumor core and mesenchymal tumor buds. Most of the cases were diagnosed as moderately differentiated adenocarcinoma (n=89; 79.46%). The majority of cases (n=100; 89.28%) exhibited a mismatch repair proficient status (microsatellite stable CRCs). A predominance of epithelial-type (n=51; 45.54%) and hybrid CRCs (n=47; 41.96%) was observed, whereas a few cases (n=14; 12.50%) were classified as mesenchymal-type CRCs. This molecular classification was associated with pathological stage (P<0.01), pT stage (P=0.04), pN stage (P<0.01), the grade of tumor budding (P=0.04), and maspin expression in both the tumor core (P=0.04) and the invasion front (P<0.01). The mesenchymal-type cases predominantly exhibited lymph node metastases, high-grade budding and a tendency towards maspin nuclear predominance. All epithelial-type cases with maspin-only expression (n=18) were non-metastatic. Patients with CRC of the epithelial subtype and those with a lymph node ratio (LNR) ≤0.15 presented the best overall survival, followed by those with hybrid and mesenchymal subtypes. Nuclear maspin positivity was more frequent in cases with a high-budding degree compared with those with a low-budding degree (P=0.03). The EMT-associated molecular classification of CRCs may be used to identify the most aggressive CRCs, which show a mesenchymal phenotype, high-budding degree, maspin nuclear positivity and lymph node metastases. The pN stage, LNR and budding degree of patients, which can be evaluated with maspin expression, remain the most important prognostic factors.

Citing Articles

The paradoxical role of SERPINB5 in gastrointestinal cancers: oncogene or tumor suppressor?.

Zeng S, Zhang J, Jiang W, Zeng C Mol Biol Rep. 2025; 52(1):188.

PMID: 39899168 DOI: 10.1007/s11033-025-10293-w.


Significance of CD70, VEGF, and CD90 Immunohistochemical Expression in Colorectal Cancer.

Aboushousha T, Osama M, Mohamed M, Khaled Y, Elmeligy H, Ossama Y Asian Pac J Cancer Prev. 2024; 25(10):3691-3699.

PMID: 39471037 PMC: 11711364. DOI: 10.31557/APJCP.2024.25.10.3691.


Malignant Transformation of Normal Oral Tissue to Dysplasia and Early Oral Squamous Cell Carcinoma: An Transcriptomics Approach.

Jamshidi S, Tavangar M, Shojaei S, Taherkhani A Anal Cell Pathol (Amst). 2024; 2024:6260651.

PMID: 39376501 PMC: 11458300. DOI: 10.1155/2024/6260651.


SALL4 upregulates brain-derived neurotrophic factor to mediate Hedgehog signaling to inhibit carboplatin sensitivity in colon adenocarcinoma.

Chen M, Liu Y, Xing W Pharmacogenomics. 2024; 25(5-6):231-240.

PMID: 38884945 PMC: 11388137. DOI: 10.1080/14622416.2024.2344429.


OLFM2 promotes epithelial-mesenchymal transition, migration, and invasion in colorectal cancer through the TGF-β/Smad signaling pathway.

Tang Y, Liu Y, Wang X, Guo H, Chen L, Hu G BMC Cancer. 2024; 24(1):204.

PMID: 38350902 PMC: 10865519. DOI: 10.1186/s12885-024-11925-3.


References
1.
Kim W, Kim J, Park D . Simple classifiers for molecular subtypes of colorectal cancer. Arab J Gastroenterol. 2017; 18(4):191-200. DOI: 10.1016/j.ajg.2017.11.007. View

2.
Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

3.
Banias L, Gurzu S, Kovacs Z, Bara T, Bara Jr T, Jung I . Nuclear maspin expression: A biomarker for budding assessment in colorectal cancer specimens. Pathol Res Pract. 2017; 213(9):1227-1230. DOI: 10.1016/j.prp.2017.07.025. View

4.
Hestetun K, Brydoy M, Myklebust M, Dahl O . Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer. Acta Oncol. 2014; 54(4):470-9. DOI: 10.3109/0284186X.2014.952386. View

5.
Yamadera M, Shinto E, Kajiwara Y, Mochizuki S, Okamoto K, Shimazaki H . Differential clinical impacts of tumour budding evaluated by the use of immunohistochemical and haematoxylin and eosin staining in stage II colorectal cancer. Histopathology. 2019; 74(7):1005-1013. DOI: 10.1111/his.13830. View